US3004894A - Therapeutic composition comprising tetracycline and a dioxolane - Google Patents

Therapeutic composition comprising tetracycline and a dioxolane Download PDF

Info

Publication number
US3004894A
US3004894A US804577A US80457759A US3004894A US 3004894 A US3004894 A US 3004894A US 804577 A US804577 A US 804577A US 80457759 A US80457759 A US 80457759A US 3004894 A US3004894 A US 3004894A
Authority
US
United States
Prior art keywords
tetracycline
dioxolane
methanol
dimethyl
vial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US804577A
Inventor
Richard H Johnson
Donald P Wallach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to US804577A priority Critical patent/US3004894A/en
Application granted granted Critical
Publication of US3004894A publication Critical patent/US3004894A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Definitions

  • the tetracycline compositions for parenteral administration have utilized water as the vehicle.
  • the administration of such aqueous preparations have had the disadvantages of slow absorption and slow systemic distribution from the site of injection and trauma and pain at the site of injection.
  • a surfactant as an aid to preparing the composition, a surfactant.
  • compositions of the present invention are useful for the administration of tetracycline and are superior to aqueous tetracycline compositions from the therapeutic standpoint in that they produce higher blood levels of tetracycline and are less painful to the patient.
  • R is a hydrogen, methyl or ethyl; R is a hydrogen, methyl, or ethyl; and R is a hydrogen, methyl, carbinol, or ethylol.
  • the preferred compound is 2,2-dimethyl-l,3-dioxolane- 4-methanol, wherein R and R are methyl and R is carbinol.
  • the other dioxolane compounds of this group suitable as a vehicle for tetracycline, are 1,3-dioxolane, 4- methyl-l,3-dioxolane, 1,3-dioxolane-4-methanol, 1,3-dioxolane-4-ethanol, 2,2-dimethyl-l,3-dioxolane, 2,2,4-t1'imethyl-1,3-dioxolane, 2,2-dimethyl-l,3-dioxolane-4-ethanol, 2,2-diethyl-l,3-dioxolane, 2,2-diethyl-4-methyl-l,3- dioxolane, 2,2-diethyl-1,3-dioxolane-4-methanol, 2,2-diethyl-1,3-dioXolane-4-
  • tetracycline as used in the specification and claims herein shall be taken to include the pharmaceutically and physiologically acceptable free base, organic and inorganic salts, as well as chelates, esters, complexes, and
  • the solubility of the free base in 2-,2-dimethyl-l,3-dioxolanel-methanol is greater than 250 mg./cc. and the inorganic acid salts such as the hydrochloride or phosphate are more slowly soluble and in concentrations of more than about 50 mg./cc. form suspensions. Whether the composition forms a solution or suspension in the dioxolane, however, the composition is therapeutically superior to the equivalent aqueous composition.
  • This invention enables a higher concentration of tetracycline up to 250 mg/cc. and more.
  • a concentration greater than 250 mg./ cc. of an insol luble tetracycline increases the viscosity of the compositions and although compositions having this increased viscosity are suitable for veterinary purposes Where use of a large needle is permissible, it is preferred that compositions for human use have a concentration of 250 mg./cc. or less. Of course, a lesser concentration can be used tothe m'nimum for therapeutic eflicacy.
  • compositions can be prepared having a tetracycline concentration from 1 mg. or less/cc. to about 500 mg./cc., it is preferred to prepare compositions having a concentration which is relevant to the usual dosage requirements.
  • the compositions are preferably supplied in unit dosage form, i.e., in single dose amounts of 1 or 2 cc. having 250 mg. of tetracycline or multiple dose amounts of 10 cc. having 2.5 g. of tetracycline.
  • another antibiotic can be included in the compositions.
  • the additional antibiotic can serve to either broaden the antibacterial speotrum of the composition or exert a synergistic eiiect with the tetracycline against particular bacteria.
  • Novobiocin can be added to the compositions of the present invention to followthe preference of current medical practice for the concurrent administration of tetracycline and novobiocin.
  • Pencillin V can also be included with tetracycline in the compositions and the two antibiotics can be present either as separate ingredients or in the form of the tetracycline salt of penicillin V.
  • a water soluble and parenterally acceptable acid is advantageously included in the compositions of the present invention wherein the tetracycline is present as the acid addition salt.
  • the addition of an acid to the composition increases further the rapid absorption and systemic distribution of the antibiotic.
  • Citric acid is the preferred acid. A concentration of about 10% w./v. citric acid is preferred for those compositions having a tetracycline concentration of about 125 mg./cc. Ascorbic acid can also be used as well as other parenterally acceptable acids such as gluconic acid, lactic acid and glycine hydrochloride.
  • a local anesthetic'agent is advantageously incorporated into the compositions of the present invention as a further aid in the reduction of pain'of the injection.
  • the anesthetic eflFect will begin several minutes after injection and lasts for several hours, onset and duration of action ranging with the particular agent used.
  • a concentration of about 0.5 to 2% w./v. is used depending upon the particular local anesthetic agent.
  • local anesthetics such as butethamine, dibucaine, procaine, tetracaine, and lidocaine, as Well as others are suitable.
  • the hydrochloride salts are usually used for those compositions having an acid present.
  • Pain can be further reduced by the inclusion of a compound capable of providing a magnesium ion, such as magnesium chloride and magnesium gluconate.
  • a compound capable of providing a magnesium ion such as magnesium chloride and magnesium gluconate.
  • Magnesium chloride is used in a preferred concentration of about 2 moles or more to 1 mole of tetracycline,
  • a surfactant in a concentration of about 0.5% is ada 3 vantageously present as an adjuvant to the preparation and administration of those compositions forming suspensions. This agent aids in the suspending of the insoluble particles in the dioxolane, insuring accurate dosage when aliquots of the composition are administered.
  • the surfactant also prevents freezing of the syringe and clogging of the lumen of the hypodermic needle. Polyoxyethylene sorbitan monolaurate is preferred.
  • compositions of the present invention are best prepared in final form at the time of administration by simply adding the dioxolane from one container to the dry powder tetracycline mixture in the other container and shaking until dispersed.
  • the final composition is to be a suspension and a surfactant is employed, the latter is deposited over the surface of the tetracycline particles.
  • the surfactant is fluid, itcan be sprayed 'over the powder; however, better distribution is obtained if the surfactant is dissolved in a volatile fluid (which is not a solvent for the tetracycline) and the solution sprayed onto the tetracycline.
  • a slurry can be made of the tetracycline and the surfactant-solvent solution, and the solvent allowed to evaporate.
  • the coated teracycline particles are then blended with the remaining ingredients until uniformly with the tetracycline powder blend.
  • Two cubic centimeter glass ampoules are aseptically filled with sterile 2,2-dimethyl-1,3-dioxolane-4-methanol and sealed.
  • the 2,2-dimethyl-1,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount sufiicient to make 2 cc. of solution.
  • the vial is shaken until the powders are dissolved and the solution withdrawn in a syringe and administered, preferably intramuscularly;
  • the prepara: tion gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • the powders are bolted through No. 9 bolting cloth and thoroughly blended.
  • the blended powder mixture is filled into vials, each vial containing 615 mg. of powder mixture.
  • the vials are sterilized by exposure to ethylene oxide vapors and capped.
  • the 2,2-dimethyl-1,3-dioxolane-4-methanol is added to the vial containing the antibiotic in an amount sufficient to make 2 cc. of solution.
  • the vial is shaken until the powders are dissolved and the solution withdrawn in a syringe and administered, preferably intramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • Example 3 G Tetracycline base, milled 287.5 Calcium acid novobiocin, micronized 143.7 a-DiethyIaminO-Z,6-aceto-xylidide 40
  • the powders are bolted through No. 9 bolting cloth and thoroughly blended.
  • the blended powder mixture is filled into vials, each vial containing 471.2 mg. of powder mixture.
  • the vials are sterilized by exposure to ethylene oxide vapors and capped.
  • the 2,2-dimethyl-1,3- dioxolane-4-methanol is added to the vial containing the antibiotics in an amount s-ufiicient to make 2 Co.
  • the vial is shaken to uniformly distribute the antibiotics and the final compositions withdrawn in a syringe and administered, preferably intramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • Example 4 Tetracycline phosphate, micronized, 1%. lecithin coated 287.5 Citric acid anhydrous, micronized 222 a-Diethylamino 2,6-aceto-xylidide hydrochloride,
  • micronized 44 The dry powders are mixed together until uniformly dispersed. 553.5 mg. of the mixture are filled into a vial, sterilized with ethylene oxide and capped.
  • dioxolane-4-methanol is added to the vial containing the antibiotic in an amount suflicient to make 2 cc. of suspension,
  • the vial. is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than, an equivalent composition utilizing an aqueous vehicle. 4
  • the 2,2-dimethyl-l,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount suflicient to make 2 cc. of suspension.
  • the vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • Example 6 G Tetracycline phosphate, micronized 287.5 Citric acid, anhydrous, micronized 220 Tetracaine hydrochloride, micronized 44 Polyoxyethylene sorbitan monolaurate 10
  • the polyoxyethylene sorbitan is dissolved in about 250 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted.
  • the chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours.
  • the tetracycline cake is comminuted and the powder blended with the remaining ingredients. 561.5 mg. of the mixture is filled into a vial, sterilized with ethylene oxide and capped.
  • the 2,2-dimethyl-1,3- dioxolane-tmethanol is added to the vial containing the antibiotic in an amount sufficient to make 2 cc. of suspension.
  • Ihe vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • the polyoxyethylene sorbitan is dissolved in about 250 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted.
  • the chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours.
  • the tetracycline cake is comminuted and the powder blended with the remaining ingredients. 561.5 mg. of the mixture is filled into a vial, sterilized with ethylene oxide and capped.
  • the 2,2-dimethy1-1,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount suflicient to make 2 cc. of suspension.
  • the vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • the polyoxyethylene sorbitan is dissolved in about 500 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted.
  • the chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours.
  • the tetracycline cake is comminuted and the powder blended with the remaining ingredients. 774 mg. of the mixture is filled into a vial, sterilized with ethylene oxide and capped.
  • the 2,2-dimethyl-1,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount sufficient to make 2 cc. of suspension.
  • the vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • Example 9 G Tetracycline phosphate, micronized 575 Polyoxyethylene sorbitan monolaurate 10
  • the polyoxyethylene sorbitan monolaurate is dissolved in about 500 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted.
  • the chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours.
  • the tetracycline cake is comminuted. 5 mg. of the powder is filled into a vial, sterilized with ethylene oxide and capped.
  • the 2,2-dimethyl-l,3- dioxolane-tmethanol is added to the vial containing the antibiotic in an amount sufficient to make 2 cc. of suspension.
  • the vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • Example 10 G 6-demethyl tetracycline, milled 287.5 u-Diethylamino-2,6-aceto-xylidide 40
  • the powders are bolted through No. 9 bolting cloth and thoroughly blended.
  • the blended powder mixture is filled into vials, each via'l containing 325.5 mg. of powder mixture.
  • the vials are sterilized by exposure to ethylene oxide vapors and capped.
  • the 2,2-dimethyl-l,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount suflicient to make 2 cc.
  • the vial is shaken to disperse the antibiotic and the composition withdrawn in a syringe and administered, preferably in tramuscularly.
  • the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
  • composition of claim 1 wherein the tetracycline is the tetracycline free base.
  • composition of claim 1 wherein the tetracycline is a acid addition salt of tetracycline free base.
  • composition of claim 1 wherein the tetracycline is the penicillin V salt of tetracycline free base.
  • composition of claim 1 whereinthetetracycline is G-demethyl tetracycline.
  • composition of claim 1 wherein the tetracycline is pyrrolidino-methyl-tetracycline.
  • a therapeutic composition for parenteral administration comprising a pharmacologically acceptable acid addition salt of tetracycline free base as an essential active ingredient, a non-toxic, parcnterally acceptable, Water soluble acid/and, as a vehicle therefor, 2,2-dimethyll ,3 -dioxolane-4-methanel.
  • a therapeutic composition for parenteral administration comprising from' about 5 mg./cc. to about 5.00 nag/cc. of tetracycline as an essential active ingredient, and, as a vehicle therefor, 2,2-dimethyl-1,3-dioxolane-4- methanol. 7.
  • a therapeutic composition for parenteral administration comprising about 12.5% tetracyclinephosphate, about 10% citric acid, about 2.0% a-diethylamino-2,6- aceto-Xylidide hydrochloride, about 0.5% polyoxyethylene sorbitan monolaurate and 2,2-dimethyl-1,3-dioxolane- 4-rnethanol.
  • a therapeutic composition for parenteral administration comprising about,12,5% tetracycline phosphate,-
  • citric. acid about 2. 0%' tetracaine hydrochloride, about 0.5 polyoxyethylene sorbitan monolaurate and 2,2-dimethyh1,3-diox0lane-4-methanol.

Description

United States Patent 3,004,894 THERAPEUTIC COMPOSITION COMPRISING TETRACYCLINE AND A DIOXOLANE Richard H. Johnson, Kalamazoo, and Donald P. Wallach, Richland, Mich., assignors to The Upjohn Company, Kalamazoo, Mich., a corporation of Delaware No Drawing. Filed Apr. 7, 1959, Ser. No. 804,577 Claims. (Cl. 167-82) This invention relates to a therapeutic composition of tetracycline and more particularly to a parenterally acceptable dosage form of tetracycline with a dioxolane vehicle.
Prior to the present invention the tetracycline compositions for parenteral administration have utilized water as the vehicle. However, the administration of such aqueous preparations have had the disadvantages of slow absorption and slow systemic distribution from the site of injection and trauma and pain at the site of injection.
The therapeutic compositions of the present invention comprise tetracycline and a dioxolane. The compositions can be either solutions or suspensions depending upon the particular form of tetracycline used, the concentration of the particular tetracycline and the presence of solubilizers. Advantageously the compositions can include a parenterally acceptable acid, a local anesthetic, a compound capable of providing a magnesium ion, and,
as an aid to preparing the composition, a surfactant.
Other antibiotics can be included in the compositions, especially novobiocin for its synergistic efiect with tetracycline.
The compositions of the present invention are useful for the administration of tetracycline and are superior to aqueous tetracycline compositions from the therapeutic standpoint in that they produce higher blood levels of tetracycline and are less painful to the patient.
The dioxolane compounds suitable for the compositions of the present invention can be represented by the following graphic formula:
R is a hydrogen, methyl or ethyl; R is a hydrogen, methyl, or ethyl; and R is a hydrogen, methyl, carbinol, or ethylol.
The preferred compound is 2,2-dimethyl-l,3-dioxolane- 4-methanol, wherein R and R are methyl and R is carbinol. The other dioxolane compounds of this group, suitable as a vehicle for tetracycline, are 1,3-dioxolane, 4- methyl-l,3-dioxolane, 1,3-dioxolane-4-methanol, 1,3-dioxolane-4-ethanol, 2,2-dimethyl-l,3-dioxolane, 2,2,4-t1'imethyl-1,3-dioxolane, 2,2-dimethyl-l,3-dioxolane-4-ethanol, 2,2-diethyl-l,3-dioxolane, 2,2-diethyl-4-methyl-l,3- dioxolane, 2,2-diethyl-1,3-dioxolane-4-methanol, 2,2-diethyl-1,3-dioXolane-4-ethanol, 2-methyl-1,3-dioxolane, 2, 4-dimethyl-L3-dioxolane, Z-methyl-l,3-dioxolane-4-methanol, 2-methyl-l,3-dioxolane-4-ethanol, 2-ethyl-l,3-dioxolane, 2-ethyl-4-methyl-1,3-dioxolane, 2-ethyl-l,3-dioxolane-4-methanol, 2-ethyl-1,3-dioxolane-4-ethanol, Z-ethyl- 2-methyl-l,3-dioxolane, 2,4-dimethyl2-ethy1-1,3-dioxolane, 2-ethyl-2-methyl-1,3-dioxolane-4-methanol, 2-ethyl- 2-methyl-1,3-dioxolane-4-ethanol.
The term tetracycline as used in the specification and claims herein shall be taken to include the pharmaceutically and physiologically acceptable free base, organic and inorganic salts, as well as chelates, esters, complexes, and
2 6-demethy1 tetracycline and pyrrolidino-methyl-tetracycline.
The solubility of the free base in 2-,2-dimethyl-l,3-dioxolanel-methanol is greater than 250 mg./cc. and the inorganic acid salts such as the hydrochloride or phosphate are more slowly soluble and in concentrations of more than about 50 mg./cc. form suspensions. Whether the composition forms a solution or suspension in the dioxolane, however, the composition is therapeutically superior to the equivalent aqueous composition.
Current medical practice utilizes aqueous compositions having a tetracycline concentration of about 50 mg./ cc. and mg./ cc. This invention enables a higher concentration of tetracycline up to 250 mg/cc. and more. A concentration greater than 250 mg./ cc. of an insol luble tetracycline increases the viscosity of the compositions and although compositions having this increased viscosity are suitable for veterinary purposes Where use of a large needle is permissible, it is preferred that compositions for human use have a concentration of 250 mg./cc. or less. Of course, a lesser concentration can be used tothe m'nimum for therapeutic eflicacy.
Although compositions can be prepared having a tetracycline concentration from 1 mg. or less/cc. to about 500 mg./cc., it is preferred to prepare compositions having a concentration which is relevant to the usual dosage requirements. To this end the compositions are preferably supplied in unit dosage form, i.e., in single dose amounts of 1 or 2 cc. having 250 mg. of tetracycline or multiple dose amounts of 10 cc. having 2.5 g. of tetracycline.
In addition to the tetracycline, another antibiotic can be included in the compositions. Advantageously the additional antibiotic can serve to either broaden the antibacterial speotrum of the composition or exert a synergistic eiiect with the tetracycline against particular bacteria. Novobiocin can be added to the compositions of the present invention to followthe preference of current medical practice for the concurrent administration of tetracycline and novobiocin. Pencillin V can also be included with tetracycline in the compositions and the two antibiotics can be present either as separate ingredients or in the form of the tetracycline salt of penicillin V.
A water soluble and parenterally acceptable acid is advantageously included in the compositions of the present invention wherein the tetracycline is present as the acid addition salt. The addition of an acid to the composition increases further the rapid absorption and systemic distribution of the antibiotic.
Citric acid is the preferred acid. A concentration of about 10% w./v. citric acid is preferred for those compositions having a tetracycline concentration of about 125 mg./cc. Ascorbic acid can also be used as well as other parenterally acceptable acids such as gluconic acid, lactic acid and glycine hydrochloride.
A local anesthetic'agent is advantageously incorporated into the compositions of the present invention as a further aid in the reduction of pain'of the injection. The anesthetic eflFect will begin several minutes after injection and lasts for several hours, onset and duration of action ranging with the particular agent used. A concentration of about 0.5 to 2% w./v. is used depending upon the particular local anesthetic agent. local anesthetics such as butethamine, dibucaine, procaine, tetracaine, and lidocaine, as Well as others are suitable. The hydrochloride salts are usually used for those compositions having an acid present.
Pain can be further reduced by the inclusion of a compound capable of providing a magnesium ion, such as magnesium chloride and magnesium gluconate. Magnesium chloride is used in a preferred concentration of about 2 moles or more to 1 mole of tetracycline,
A surfactant in a concentration of about 0.5% is ada 3 vantageously present as an adjuvant to the preparation and administration of those compositions forming suspensions. This agent aids in the suspending of the insoluble particles in the dioxolane, insuring accurate dosage when aliquots of the composition are administered. The surfactant also prevents freezing of the syringe and clogging of the lumen of the hypodermic needle. Polyoxyethylene sorbitan monolaurate is preferred.
The compositions of the present invention are best prepared in final form at the time of administration by simply adding the dioxolane from one container to the dry powder tetracycline mixture in the other container and shaking until dispersed.
In preparing the dry powder mixture the various dry ingredients are first reduced to a finely divided state. Examples of the many ways in which comminution can be carried out can be found in chapter 11 of Remingtons Practice of Pharmacy, 11th edition, Mack Publishing Company, Easton, Pennsylvania, U.S.A., 1956. The preferred method of reducing the particle size of the various ingredients is by use of an air micronizer; particles so reduced by this method will hereinafter be described as micronized. i
When the final composition is to be a suspension and a surfactant is employed, the latter is deposited over the surface of the tetracycline particles. If the surfactant is fluid, itcan be sprayed 'over the powder; however, better distribution is obtained if the surfactant is dissolved in a volatile fluid (which is not a solvent for the tetracycline) and the solution sprayed onto the tetracycline. Alternatively, a slurry can be made of the tetracycline and the surfactant-solvent solution, and the solvent allowed to evaporate. The coated teracycline particles are then blended with the remaining ingredients until uniformly with the tetracycline powder blend.
. The following examples are illustrative of the process and products of the present invention, but are not to be construed as limiting.
' Example 1 I a G, Tetracycline base, milled 287.5 a-Diethylamino-2,fi-aceto-xylidide 40 The powders are bolted through No. 9 bolting cloth and thoroughly blended. The blended powder mixture is, filled into vials, each vial containing 327,5 mg. of powder mixture. The vials are sterilized by exposure to ethylene oxide vapors and capped.
Two cubic centimeter glass ampoules are aseptically filled with sterile 2,2-dimethyl-1,3-dioxolane-4-methanol and sealed.
At the time for administration the 2,2-dimethyl-1,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount sufiicient to make 2 cc. of solution. The vial is shaken until the powders are dissolved and the solution withdrawn in a syringe and administered, preferably intramuscularly; When so used, the prepara: tion gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
a-Diethylamino-2,6-aceto-xylidide The powders are bolted through No. 9 bolting cloth and thoroughly blended. The blended powder mixture is filled into vials, each vial containing 615 mg. of powder mixture. The vials are sterilized by exposure to ethylene oxide vapors and capped.
Two cubic centimeterlglass ar'npoules are aseptically filled with V sterile 2;,2-dimethyl-1,3-dioxolane-4-methanol and sealed. 7 7
At the time for administration the 2,2-dimethyl-1,3-dioxolane-4-methanol is added to the vial containing the antibiotic in an amount sufficient to make 2 cc. of solution. The vial is shaken until the powders are dissolved and the solution withdrawn in a syringe and administered, preferably intramuscularly. Whenso used, the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
Example 3 G. Tetracycline base, milled 287.5 Calcium acid novobiocin, micronized 143.7 a-DiethyIaminO-Z,6-aceto-xylidide 40 The powders are bolted through No. 9 bolting cloth and thoroughly blended. The blended powder mixture is filled into vials, each vial containing 471.2 mg. of powder mixture. The vials are sterilized by exposure to ethylene oxide vapors and capped.
Two cubic centimeter glass ampoules are aseptically filled with sterile 2,2-dimethyl-1,3-dioxolane-4-methanol and sealed.
' At the time for administration the 2,2-dimethyl-1,3- dioxolane-4-methanol is added to the vial containing the antibiotics in an amount s-ufiicient to make 2 Co. The vial is shaken to uniformly distribute the antibiotics and the final compositions withdrawn in a syringe and administered, preferably intramuscularly. When so used, the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
Example 4 Tetracycline phosphate, micronized, 1%. lecithin coated 287.5 Citric acid anhydrous, micronized 222 a-Diethylamino 2,6-aceto-xylidide hydrochloride,
micronized 44 The dry powders are mixed together until uniformly dispersed. 553.5 mg. of the mixture are filled into a vial, sterilized with ethylene oxide and capped.
1.9 cc. of sterilized 2,2-dimethyl-1,3-dioxo1ane-4-methanol is aseptically filled into a glass vial and sealed.
At the time for administration the 2,2-dimethyl-l,3-
. dioxolane-4-methanol is added to the vial containing the antibiotic in an amount suflicient to make 2 cc. of suspension, The vial. is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly. When so used, the preparation gives less pain and higher tetracycline blood levels than, an equivalent composition utilizing an aqueous vehicle. 4
The polyoxyethylene sorbitan is dissolved in about 250 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted. The chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours. The tetracycline cake is comminuted and the powder blended With the remaining ingredients. 561.5 mg. of the mixture is filled into a vial, sterilized with ethylene oxide, and capped.
1.9 cc. of 2,2-dimethyl-1,3-dioxolane-4-methanol is aseptically filled into a glass vial and sealed.
At the time for administration the 2,2-dimethyl-l,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount suflicient to make 2 cc. of suspension. The vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly. When so used, the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
Example 6 G. Tetracycline phosphate, micronized 287.5 Citric acid, anhydrous, micronized 220 Tetracaine hydrochloride, micronized 44 Polyoxyethylene sorbitan monolaurate 10 The polyoxyethylene sorbitan is dissolved in about 250 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted. The chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours. The tetracycline cake is comminuted and the powder blended with the remaining ingredients. 561.5 mg. of the mixture is filled into a vial, sterilized with ethylene oxide and capped.
1.9 cc. of sterilized 2,2-dimethyl-1,3-dioxolane-4-methanol is aseptically filled into a glass vial and sealed.
At the time for administration the 2,2-dimethyl-1,3- dioxolane-tmethanol is added to the vial containing the antibiotic in an amount sufficient to make 2 cc. of suspension. Ihe vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly. When so used, the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
The polyoxyethylene sorbitan is dissolved in about 250 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted. The chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours. The tetracycline cake is comminuted and the powder blended with the remaining ingredients. 561.5 mg. of the mixture is filled into a vial, sterilized with ethylene oxide and capped.
1.9 cc. of sterilized 2,2-dimethyl-1,3-dioxolane-4-rncthanol is aseptically filled into a glass vial and sealed.
At the time for administration the 2,2-dimethy1-1,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount suflicient to make 2 cc. of suspension. The vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly. When so used, the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
The polyoxyethylene sorbitan is dissolved in about 500 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted. The chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours. The tetracycline cake is comminuted and the powder blended with the remaining ingredients. 774 mg. of the mixture is filled into a vial, sterilized with ethylene oxide and capped.
p 1.9 cc. of 2,2-dimethyl-1,3-dioxolane-4-methanol is aseptically filled into a glass vial and sealed.
At the time for administration the 2,2-dimethyl-1,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount sufficient to make 2 cc. of suspension. The vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly. When so used, the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
Example 9 G. Tetracycline phosphate, micronized 575 Polyoxyethylene sorbitan monolaurate 10 The polyoxyethylene sorbitan monolaurate is dissolved in about 500 cc. of chloroform and the solution mixed with the tetracycline until the tetracycline particles are uniformly wetted. The chloroform is allowed to evaporate and the cake dried at 40 C. for 2 hours. The tetracycline cake is comminuted. 5 mg. of the powder is filled into a vial, sterilized with ethylene oxide and capped.
1.9 cc. of 2,2-dimethyl-1,3-dioxolane-4-methanol is aseptically filled into a glass vial and sealed.
At the time for administration the 2,2-dimethyl-l,3- dioxolane-tmethanol is added to the vial containing the antibiotic in an amount sufficient to make 2 cc. of suspension. The vial is shaken to suspend the antibiotic and the suspension withdrawn in a syringe and administered, preferably intramuscularly. When so used, the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
Example 10 G 6-demethyl tetracycline, milled 287.5 u-Diethylamino-2,6-aceto-xylidide 40 The powders are bolted through No. 9 bolting cloth and thoroughly blended. The blended powder mixture is filled into vials, each via'l containing 325.5 mg. of powder mixture. The vials are sterilized by exposure to ethylene oxide vapors and capped.
1.9 cc. of sterilized 2,2-climethyl-l,3-dioxolane-4-methano] is aseptically filled into a glass vial and sealed.
At the time for administration the 2,2-dimethyl-l,3- dioxolane-4-methanol is added to the vial containing the antibiotic in an amount suflicient to make 2 cc. The vial is shaken to disperse the antibiotic and the composition withdrawn in a syringe and administered, preferably in tramuscularly. When so used, the preparation gives less pain and higher tetracycline blood levels than an equivalent composition utilizing an aqueous vehicle.
It is to be understood that the invention is not to be limited to the exact details of operation or exact compounds shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art, and the invention is therefore to be limited only by the scope of the appended claims.
We claim:
1. A therapeutic composition for parenteral administration comprising tetracycline as an essential active ingredient and, as a vehicle therefor, 2,2-dimethyl-l,3-diox- =olane-4-methanol.
2. The composition of claim 1 wherein the tetracycline is the tetracycline free base.
3. The composition of claim 1 wherein the tetracycline is a acid addition salt of tetracycline free base.
4. The composition of claim 1 wherein the tetracycline is the penicillin V salt of tetracycline free base.
5. The composition of claim 1 whereinthetetracycline is G-demethyl tetracycline. t
6. The composition of claim 1 wherein the tetracycline is pyrrolidino-methyl-tetracycline.
7. A therapeutic composition for parenteral administration comprising a pharmacologically acceptable acid addition salt of tetracycline free base as an essential active ingredient, a non-toxic, parcnterally acceptable, Water soluble acid/and, as a vehicle therefor, 2,2-dimethyll ,3 -dioxolane-4-methanel.
8. A therapeutic composition for parenteral administration comprising from' about 5 mg./cc. to about 5.00 nag/cc. of tetracycline as an essential active ingredient, and, as a vehicle therefor, 2,2-dimethyl-1,3-dioxolane-4- methanol. 7.
9. A therapeutic composition for parenteral administration comprising about 12.5% tetracyclinephosphate, about 10% citric acid, about 2.0% a-diethylamino-2,6- aceto-Xylidide hydrochloride, about 0.5% polyoxyethylene sorbitan monolaurate and 2,2-dimethyl-1,3-dioxolane- 4-rnethanol.
10. A therapeutic composition for parenteral administration comprising about,12,5% tetracycline phosphate,-
about 10% citric. acid, about 2. 0%' tetracaine hydrochloride, about 0.5 polyoxyethylene sorbitan monolaurate and 2,2-dimethyh1,3-diox0lane-4-methanol.
ReferencesCited in the fileof this patent UNITED STATES PATENTS 2,428,805 Kharasch Oct. 14, 1947 FOREIGN PATENTS 279,099 Switzerland Mar. 1, 1952 535,471 Canada Jan. 8, 1957 793,558 Great Britain Apr. 16, 1958 OTHER REFERENCES UNITED STATES PATENT OFFICE M CERTIFICATE OF CORRECTION Patent N0. 3,004,894 October 17, 1961 Richard H. Johnson et alo It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below.
Column 3, line 33 for "teracycline" read tetracycline line 56, for "327, 5 mg.
read 327.5 mg column 5 l ne 68 for "200" read 220 column 6 line 73 after "is a" lnsert pharmacologically acceptable Signed and sealed this 10th day of April 1962.
(SEAL) Attest:
ERNEST W. SWIDER DAVID L. LADD Commissioner of Patents Attesting Officer

Claims (1)

1. A THERAPEUTIC COMPOSITION FOR PARENTERAL ADMINISTRATION COMPRISING TETRACYCLINE AS AN ESSENTIAL ACTIVE INGREDIENT AND, AS A VEHICLE THEREFOR, 2,2-DIMETHYL-1,3-DIOXOLANE-4-METHANOL.
US804577A 1959-04-07 1959-04-07 Therapeutic composition comprising tetracycline and a dioxolane Expired - Lifetime US3004894A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US804577A US3004894A (en) 1959-04-07 1959-04-07 Therapeutic composition comprising tetracycline and a dioxolane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US804577A US3004894A (en) 1959-04-07 1959-04-07 Therapeutic composition comprising tetracycline and a dioxolane

Publications (1)

Publication Number Publication Date
US3004894A true US3004894A (en) 1961-10-17

Family

ID=25189320

Family Applications (1)

Application Number Title Priority Date Filing Date
US804577A Expired - Lifetime US3004894A (en) 1959-04-07 1959-04-07 Therapeutic composition comprising tetracycline and a dioxolane

Country Status (1)

Country Link
US (1) US3004894A (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137627A (en) * 1962-03-12 1964-06-16 Bristol Myers Co Nu-(1-pyrrolidinomethyl) tetracycline and acid compositions for aqueous acidified injections having a ph of not more than about 4
FR2034890A1 (en) * 1969-03-13 1970-12-18 Diamond Shamrock Corp
EP0038013A2 (en) * 1980-04-10 1981-10-21 Sds Biotech Corporation Injectable oxytetracycline compositions
US5391785A (en) * 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
WO2004087117A2 (en) * 2003-04-02 2004-10-14 Bayer Healthcare Ag Use of cyclic acetals/ketals for improved penetration of active substances into cells and organs
WO2009143175A2 (en) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Sensory-specific local anesthesia and prolonged duration local anesthesia
US20110178162A1 (en) * 2005-10-14 2011-07-21 Medical University Of South Carolina Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US8975268B2 (en) 2013-03-15 2015-03-10 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
WO2011138678A3 (en) * 2010-05-04 2016-05-26 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2428805A (en) * 1947-10-14 Dioxolanes and methods of
CH279099A (en) * 1948-01-13 1951-11-15 Sharp & Dohme Inc Process for the production of a bacteriostatic preparation.
CA535471A (en) * 1957-01-08 Heinemann Bernard Therapeutically useful tetracycline complex
GB793558A (en) * 1954-07-07 1958-04-16 Pfizer Improvements in or relating to tetracycline preparations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2428805A (en) * 1947-10-14 Dioxolanes and methods of
CA535471A (en) * 1957-01-08 Heinemann Bernard Therapeutically useful tetracycline complex
CH279099A (en) * 1948-01-13 1951-11-15 Sharp & Dohme Inc Process for the production of a bacteriostatic preparation.
GB793558A (en) * 1954-07-07 1958-04-16 Pfizer Improvements in or relating to tetracycline preparations

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137627A (en) * 1962-03-12 1964-06-16 Bristol Myers Co Nu-(1-pyrrolidinomethyl) tetracycline and acid compositions for aqueous acidified injections having a ph of not more than about 4
FR2034890A1 (en) * 1969-03-13 1970-12-18 Diamond Shamrock Corp
EP0038013A2 (en) * 1980-04-10 1981-10-21 Sds Biotech Corporation Injectable oxytetracycline compositions
EP0038013A3 (en) * 1980-04-10 1982-09-22 Sds Biotech Corporation Injectable oxytetracycline compositions
US5391785A (en) * 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
US5726329A (en) * 1990-01-16 1998-03-10 La Jolla Pharmaceutical Company Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
US5786512A (en) * 1990-01-16 1998-07-28 Lajolla Pharmaceutical Company Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
US5874552A (en) * 1990-01-16 1999-02-23 La Jolla Pharmaceutical Company Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
WO2004087117A2 (en) * 2003-04-02 2004-10-14 Bayer Healthcare Ag Use of cyclic acetals/ketals for improved penetration of active substances into cells and organs
US20070270503A1 (en) * 2003-04-02 2007-11-22 Bayer Healthcare Ag Penetration of Active Substances Into Cells and Organs
WO2004087117A3 (en) * 2003-04-02 2005-02-10 Bayer Healthcare Ag Use of cyclic acetals/ketals for improved penetration of active substances into cells and organs
US7652071B2 (en) 2003-04-02 2010-01-26 Alpha-Biocare Gmbh Penetration of active substances into cells and organs
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20110178162A1 (en) * 2005-10-14 2011-07-21 Medical University Of South Carolina Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8609733B2 (en) 2008-05-19 2013-12-17 Massachusetts Institute Of Technology Sensory-specific local anesthesia and prolonged duration local anesthesia
US20110086922A1 (en) * 2008-05-19 2011-04-14 Massachusetts Institute Of Technology Sensory-specific local anesthesia and prolonged duration local anesthesia
WO2009143175A3 (en) * 2008-05-19 2010-10-28 Children's Medical Center Corporation Sensory-specific local anesthesia and prolonged duration local anesthesia
WO2009143175A2 (en) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Sensory-specific local anesthesia and prolonged duration local anesthesia
US9249150B2 (en) 2009-03-24 2016-02-02 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
WO2011138678A3 (en) * 2010-05-04 2016-05-26 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10881647B2 (en) 2013-03-15 2021-01-05 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US8975281B2 (en) 2013-03-15 2015-03-10 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US10314833B2 (en) 2013-03-15 2019-06-11 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US8975268B2 (en) 2013-03-15 2015-03-10 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne

Similar Documents

Publication Publication Date Title
US3004894A (en) Therapeutic composition comprising tetracycline and a dioxolane
US2515898A (en) Procaine penicillin and therapeutic compositions
EP0602586B1 (en) Stable pharmaceutical composition of fumagillol derivatives
ES2145115T4 (en) INJECTABLE COMPOSITIONS BASED ON TAXANOS DERIVATIVES.
KR19990067603A (en) Aqueous suspension of 9-hydroxyrisperidone fatty acid ester
JP4234198B2 (en) Compounds for veterinary and medical applications
JP2012167132A (en) FREEZE-DRIED PREPARATION OF N-[o-(p-PIVALOYLOXY BENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE
DE102004063347A1 (en) Ready-to-use gemcitabine solutions and gemcitabine solution concentrates
US2795528A (en) Therapeutic composition containing a tetracycline and a phosphate other than orthophosphate
US3337400A (en) Aqueous post-surgical injection by infiltration with a local anesthetic, a substantially water-insoluble, local anti-inflammatory gluco corticoid, and an antibiotic
US2619447A (en) Injectable penicillin preparations
US5002940A (en) Solid drug formulations and stable suspensions
EP1618894B1 (en) Composition for injection
US2966442A (en) Antibiotic compositions
US2518510A (en) Stable injectable oil-pectin therapeutic compositions
US3900561A (en) Pharmaceutical compositions
ES2215856T3 (en) SOLUTION OF MONOSODIC SALT TETRAHYDRATE OF N- (O- (P-PIVALOYLOXIBENCENO-SULFONYLAMINE) BENZOIL) GLYCINE AND MEDICINAL PRODUCT CONTAINING THIS SOLUTION.
US2856329A (en) Methods of administering steroid hormone solutions
US2791531A (en) Erythromycin thiocyanate and compositions containing same
RU2023449C1 (en) Method of stabilization of 4-ethyl-2-hydroxyimino-5-nitro-3-hexeneamide
HU191538B (en) Process for producing pharmaceutical compositions containing acid additional salts of vinca-dimeres
US4039668A (en) Corticoid-containing inhalants
US2472453A (en) Streptomycin composition of reduced toxicity
US2676961A (en) Procaine-penicillin preparation
US3737545A (en) Alpha-aminobenzyl penicillins